Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy

Authors

Deepa Chand, Washington University School of Medicine in St. Louis
Franziska Mohr, Novartis Gene Therapies
Hugh McMillan, University of Ottawa
Francis Fonyuy Tukov, Novartis International AG
Kyle Montgomery, Novartis Gene Therapies
Aaron Kleyn, Novartis Gene Therapies
Rui Sun, Novartis Gene Therapies
Sitra Tauscher-Wisniewski, Novartis Gene Therapies
Petra Kaufmann, Novartis Gene Therapies
Gerd Kullak-Ublick, University of Zurich

Journal

Journal of Hepatology

Publication Date

3-1-2021

Volume

74

Issue

3

First Page

560

Last Page

566

Document Type

Open Access Publication

DOI

10.1016/j.jhep.2020.11.001

Rights and Permissions

Chand D, Mohr F, McMillan H, Tukov FF, Montgomery K, Kleyn A, Sun R, Tauscher-Wisniewski S, Kaufmann P, Kullak-Ublick G. Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy. J Hepatol. 2021 Mar;74(3):560-566. doi: 10.1016/j.jhep.2020.11.001. © 2020 European Association for the Study of the Liver. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Chand, Deepa; Mohr, Franziska; McMillan, Hugh; Tukov, Francis Fonyuy; Montgomery, Kyle; Kleyn, Aaron; Sun, Rui; Tauscher-Wisniewski, Sitra; Kaufmann, Petra; and Kullak-Ublick, Gerd, "Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy." Journal of Hepatology. 74, 3. 560 - 566. (2021).
https://digitalcommons.wustl.edu/oa_4/2896

Additional Links

Supplemental material is available for this article at publisher site.